Nektar Therapeutics stock gains after Q2 loss narrows

Published on 09/18/2026 at 12:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Nektar Therapeutics stock has climbed strongly in 2026, with shares closing at USD 68.36 on September 17, 2026 on Nasdaq. The company reported a Q2 2026 net loss of USD 40.62 million on revenue of USD 10.13 million, narrowing its loss versus a year earlier.

NKTR, US6354171056, Illustration mit AI erstellt.

Nektar Therapeutics stock (ISIN US6354171056) continued its 2026 recovery, closing at USD 68.36 on Nasdaq on September 17, 2026, up 61.7% from the USD 42.28 level at the start of the year per data from MarketBeat.

Q2 2026 results show smaller loss

According to Yahoo Finance, Nektar reported revenue of USD 10.13 million in Q2 2026, with a net loss of USD 40.62 million for the quarter ended June 30, 2026.

The same Yahoo Finance overview shows that in Q2 2025 Nektar generated revenue of USD 11.79 million, implying that sales declined by 11.65% year on year in Q2 2026.

Profitability and margins remain under pressure

Data in the Yahoo Finance analysis section indicate that Nektar's Q2 2026 profit margin was a negative 400.97%, underlining that the company is still deep in the red despite the narrower earnings loss per share.

For investors, one key point is that Q2 2026 earnings per share came in at negative USD 1.21, compared with negative USD 1.87 in Q2 2025, meaning the per-share loss improved by USD 0.66 over the year according to the same Yahoo Finance figures.

Stock price momentum and market context

As MarketBeat reports in its stock overview updated on September 17, 2026, Nektar Therapeutics stock closed that day at USD 68.36 on Nasdaq, with an after-hours indication of USD 68.68, and the site notes that the shares have risen 61.7% from USD 42.28 at the beginning of 2026.

That performance places the stock in a strong uptrend for the year, even though the company continues to post negative earnings and margins; for long-term holders, the improvement in loss per share and the expectation of 2026 revenue of USD 41.88 million compared with USD 55.23 million in 2025 suggest a period of transition, based on the consensus estimates shown in the Yahoo Finance analysis page.

Next earnings date and trading reference

According to the company calendar section on MarketBeat, Nektar's last earnings release took place on August 13, 2026, and the next estimated earnings date is November 5, 2026, with the fiscal year ending December 31, 2026.

On September 17, 2026, Nektar Therapeutics stock used in this article traded on Nasdaq in US dollars, with USD 68.36 serving as the reference closing price for the analysis.